Aktis Oncology (NASDAQ:AKTS) Cut to “Sell” at Wall Street Zen

Wall Street Zen downgraded shares of Aktis Oncology (NASDAQ:AKTS) from a hold rating to a sell rating in a research note published on Saturday morning.

A number of other analysts have also commented on the stock. William Blair started coverage on shares of Aktis Oncology in a report on Wednesday, April 29th. They set an “outperform” rating for the company. Raymond James Financial began coverage on Aktis Oncology in a research note on Monday, June 15th. They issued a “strong-buy” rating and a $40.00 price target on the stock. Weiss Ratings upgraded Aktis Oncology from a “sell (d)” rating to a “sell (d+)” rating in a research report on Tuesday, June 23rd. JPMorgan Chase & Co. lifted their price objective on Aktis Oncology from $30.00 to $33.00 and gave the stock an “overweight” rating in a research note on Tuesday, July 14th. Finally, HC Wainwright upped their price objective on Aktis Oncology from $33.00 to $35.00 and gave the company a “buy” rating in a report on Tuesday, June 2nd. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Aktis Oncology currently has an average rating of “Moderate Buy” and a consensus price target of $34.60.

Aktis Oncology Trading Up 1.3%

Aktis Oncology stock opened at $24.21 on Friday. The firm has a market cap of $1.29 billion and a P/E ratio of -63.71. Aktis Oncology has a 1 year low of $14.72 and a 1 year high of $34.19. The company’s 50-day simple moving average is $23.98.

Aktis Oncology (NASDAQ:AKTS) last issued its quarterly earnings results on Monday, May 11th. The technology company reported ($0.38) EPS for the quarter, missing the consensus estimate of ($0.37) by ($0.01). The firm had revenue of $3.23 million for the quarter, compared to the consensus estimate of $2.23 million. On average, research analysts expect that Aktis Oncology will post -1.64 earnings per share for the current fiscal year.

Aktis Oncology Company Profile

Aktis Oncology (NASDAQ: AKTS) is a biotechnology company focused on the discovery and development of new therapies for cancer. The firm concentrates on advancing oncology candidates through research and development with the goal of addressing unmet medical needs in oncology. Its work emphasizes targeted and precision approaches intended to improve the safety and efficacy profiles of cancer treatments.

The company’s activities include laboratory research, preclinical studies and clinical development as it advances its pipeline programs toward regulatory milestones.